Disease/Infection News

RSS

Most COVID-19 patients have neurological symptoms

In a new study, published in the journal JAMA Network, University of Pittsburgh researchers for the Global Consortium Study of Neurologic Dysfunction in COVID-19 found that neurological manifestations were prevalent among patients hospitalized with COVID-19. The patients were also at a higher risk of in-hospital mortality.

17 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

New framework could help manage COVID-19, deal with other major stresses

A new analysis of the effects of SARS-CoV-2, the virus causing the current pandemic, on the human body has provided novel insights into the nature of resilience and how we deal with stressful situations.

17 May 2021

New way to detect a diverse range of bacteria that cause diarrheal disease in informal settlements

Monash University researchers have validated a way to successfully detect a diverse range of bacteria (pathogens) that cause diarrheal disease in informal settlements.

17 May 2021

A SARS-CoV-2 neutralizing antibody with extensive spike binding coverage

In a recently published research paper in the journal Nature Communications, a team of scientists from China has described the antiviral efficacy of a novel anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody isolated from recovered coronavirus disease 2019 (COVID-19) patients.

17 May 2021

Nanopore analysis identifies pseudouridine modifications in SARS-CoV-2

In a paper recently uploaded to the preprint server bioRxiv* by Fleming, Mathewson & Burrows (May 10th, 2021), nanopore devices are developed that allow identification of the passage of pseudouridine through a protein sensor. This further allowed the group to identify five conserved pseudouridine sites on the 3’ end of SARS-CoV-2 sub-genomic RNAs, which could potentially be beneficial to the virus in immune evasion.

17 May 2021

Antibody to SARS-CoV-2 inhibits complement hyperactivation

Although several monoclonal antibodies against the SARS-CoV-2 spike protein have been developed and clinically tested, little is known about antibodies to the nucleocapsid protein. In a paper published recently in the journal Nature Communications, researchers report a human monoclonal antibody that targets the nucleocapsid protein.

17 May 2021

Online gambling grew six-fold among regular gamblers during lockdown

Regular gamblers were more than six times more likely to gamble online compared to before the COVID-19 pandemic, according to new research.

17 May 2021

SARS-CoV-2 Nsp2 structure revealed by cryo-EM and AI

Researchers in the United States analyzed the non-structural protein 2 (Nsp2) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in order to better understand its function and to guide future drug discovery. The research paper is currently available on bioRxiv* preprint server.

16 May 2021

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults

Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.

16 May 2021

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

The World Health Organization (WHO) has labeled the double mutant B.1.617 variant — first discovered in India —a variant of concern for its high transmission rate and ability to evade immune responses. New research posted to the preprint server bioRxiv finds B.1.617 can modestly reduce neutralizing antibody responses generated from the Pfizer-BioNTech vaccine.

16 May 2021

Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants

Researchers in the United States have conducted a study showing the efficacy of the Moderna and Pfizer-BioNTech vaccines at eliciting a robust T cell response against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

16 May 2021

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

Researchers in Germany have demonstrated the preclinical effectiveness of a next-generation coronavirus disease 2019 (COVID-19) vaccine at enhancing antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 May 2021

Newly-developed respirator hood is a safe, effective personal protective equipment for COVID-19

Research by the University of Southampton and University Hospital Southampton has demonstrated that a newly-developed respirator hood is a safe form of personal protective equipment (PPE) for frontline healthcare workers and support staff.

15 May 2021

UCL scientists identify new immunotherapy to combat hepatitis B virus

Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world.

14 May 2021

Unique pre-clinical model enables study of HIV infection and testing of new therapies

A team led by researchers at Weill Cornell Medicine and Children's National Hospital has developed a unique pre-clinical model that enables the study of long-term HIV infection, and the testing of new therapies aimed at curing the disease.

14 May 2021

What can ancient feces tell us about the evolution of the human gut microbiome?

Researchers at the Section on Pathophysiology and Molecular Pharmacology, Joslin Diabetes Center in Boston, Massachusetts, analyzed microbial DNA found in indigenous human paleofeces (desiccated excrement) from dry caves in northern Mexico and Utah. They found that the ancient human gut microbiome is similar to those of modern-day people from non-industrialized populations.

14 May 2021

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years. In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death.

From AstraZeneca 14 May 2021

Supercarriers: Just 2% of SARS-CoV-2 positive people carry 90% of the virus

A new study published in the Proceedings of the National Academy of Sciences shows that the vast majority of the viral load in a community at any given point is present in a very small minority of the infected population, underlining the vast differences in viral loads between individuals.

14 May 2021

A look at how coronavirus disease (COVID-19) affects Parkinson's

Earlier, herpes simplex virus (HSV), influenza virus A, measles virus, cytomegalovirus (CMV), and mumps virus have all been associated with after-effects of the virus that includes Parkinson's disease (PD). This list may now include SARS-CoV-2.

14 May 2021

Disease/Infection News

Most COVID-19 patients have neurological symptoms

Nanotechnology and COVID-19 diagnosis and treatment

New framework could help manage COVID-19, deal with other major stresses

New way to detect a diverse range of bacteria that cause diarrheal disease in informal settlements

A SARS-CoV-2 neutralizing antibody with extensive spike binding coverage

Nanopore analysis identifies pseudouridine modifications in SARS-CoV-2

Antibody to SARS-CoV-2 inhibits complement hyperactivation

Online gambling grew six-fold among regular gamblers during lockdown

SARS-CoV-2 Nsp2 structure revealed by cryo-EM and AI

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

Newly-developed respirator hood is a safe, effective personal protective equipment for COVID-19

UCL scientists identify new immunotherapy to combat hepatitis B virus

Unique pre-clinical model enables study of HIV infection and testing of new therapies

What can ancient feces tell us about the evolution of the human gut microbiome?

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Supercarriers: Just 2% of SARS-CoV-2 positive people carry 90% of the virus

A look at how coronavirus disease (COVID-19) affects Parkinson's

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News